Dibotermin alfa; Recombinant human bone morphogenetic protein-2 (rhBMP-2)

Specification

• Cat#: THP-0030
• Product Name: Dibotermin alfa; Recombinant human bone morphogenetic protein-2 (rhBMP-2)
• Cas No: 246539-15-1
• Description: The product is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line. rhBMP is a disulfide-linked dimeric protein molecule with two major subunit species of 114 and 131 amino acids. Each subunit is glycosylated with high-mannose-type glycans.
• Sequences: Not Available
• Species: Human
• Molecular Weight: Not Available
• Source: CHO
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Endotoxin: <0.001 EU per 1 μg of the peptide by the LAL method
• Application: indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation.indicated for single-level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non-operative treatment for this condition.
• Concentration: 1.5 mg/ml

Pharmaceutical Information

• Pharmaceutical Application: Dibotermin alfa
• Targets: Target 1. Bone morphogenetic protein receptor type-2; Target 2. Bone morphogenetic protein receptor type-1A

Related Reading

Background of Dibotermin alfa

Dibotermin alfa, is a breakthrough in regenerative and reconstructive medicine. Dibotermin alfa is an engineered version of the human protein, bone morphogenetic protein-2 (BMP-2), which plays a vital role in the formation of bones and cartilage. The breakthrough was discovered in the late 20th century, as researchers noticed some proteins played critical roles in inducing cellular differentiation into bone cells. Gene sequencing of the human genome led to the determination of the BMP-2 locus on chromosome 20. Various crystallographic studies have been carried out to uncover the protein structure of Dibotermin alfa. It is a disulfide-linked homodimer characterized by seven structurally conserved cysteine residues adopting a cystine knot configuration.

Dibotermin alfa - related signaling pathways and function

The central function of Dibotermin alfa lies in its capability to induce bone growth. However, it also plays a role in cell differentiation, homeostasis, embryogenesis, and the development of various tissues. This is all coordinated through pathways and mechanisms activated once the Dibotermin alfa initiates a signal on BMP receptors on the cell surface.
One such pathway is the SMAD protein signaling pathway. When Dibotermin alfa binds to a BMP receptor, it induces the phosphorylation of regulatory SMAD (rSMAD) proteins. These proteins then bind to the common partner SMAD4, resulting in the transcription of numerous genes involved in bone development. Should this process go awry, various diseases related to bone formation and homeostasis may arise.

Dibotermin alfa related diseases

In the context of disease, studies have indicated that Dibotermin alfa could play a significant role in ankylosing spondylitis, a chronic inflammatory disease that affects the spine and other large joints. This is due to the overactivation of the BMP signaling pathway. Moreover, Dibotermin alfa has also been implicated in fibrodysplasia ossificans progressiva (FOP), a rare and disabling genetic condition characterized by progressive ossification within soft tissues.
The ability of Dibotermin alfa to promote bone growth has been incorporated within medicine to aid in spinal fusion surgeries and to repair tibial nonunion, where the bone fails to heal. This has transformed the approach to these surgeries, minimizing the need for bone grafts, thanks to the osteoinductive properties of Dibotermin alfa.
Further research into Dibotermin alfa has uncovered several drug candidates. These include the BMP-2 inhibitors, which have a crucial role in controlling bone growth, especially in conditions where there is overactive BMP signaling such as FOP. Drugs that target SMAD proteins, downstream elements in the BMP signaling pathway, have also been developed. Ultimately, such drugs aim to harness the benefits of Dibotermin alfa while managing potential complications related to overactivation of the BMP-2 pathway.
In conclusion, Dibotermin alfa is an incredibly influential medical breakthrough, revolutionizing regenerative medicine. This recombinant human BMP-2 protein fosters bone growth, provides innovative solutions to complex surgeries, and opens up the possibility of treatment for diseases where the bone formation process is disordered. The scientific enquiry into Dibotermin alfa’s structure and function is continually unveiling new therapeutic avenues, promising an exciting future for the world of medicine.